HCV-targeted antivirals: current status and future challenges.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Current pharmaceutical design

• Publication date

  2014-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/13816128113199990630PMID 24001232
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structure–Activity Relationships in the Development of Allosteric Hepatitis C Virus RNA‐Dependent RNA Polymerase Inhibitors: Ten Years of Research

  2013cited by this paper
• Direct-acting antiviral agents for hepatitis C virus infection.

  2013cited by this paper
• Identification of Non-Macrocyclic Small Molecule Inhibitors against the NS3/4A Serine Protease of Hepatitis C Virus through in Silico Screening

  2012cited by this paper
• Preclinical Characterization of GS-9669, a Thumb Site II Inhibitor of the Hepatitis C Virus NS5B Polymerase

  2012cited by this paper
• 3-heterocyclyl quinolone inhibitors of the HCV NS5B polymerase.

  2012cited by this paper
• Discovery of substituted N-phenylbenzenesulphonamides as a novel class of non-nucleoside hepatitis C virus polymerase inhibitors.

  2012cited by this paper
• Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients

  2012cited by this paper
• Current status and future directions in the management of chronic hepatitis C

  2012cited by this paper
• Ketoamide Resistance and Hepatitis C Virus Fitness in Val55 Variants of the NS3 Serine Protease

  2012cited by this paper
• MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants

  2012cited by this paper
• The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus.

  2012cited by this paper
• Inhibition of hepatitis C virus NS3 helicase by manoalide.

  2012cited by this paper
• Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein.

  2012cited by this paper
• A highly selective structure-based virtual screening model of Palm I allosteric inhibitors of HCV Ns5b polymerase enzyme and its application in the discovery and optimization of new analogues.

  2012cited by this paper
• The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors

  2012cited by this paper
• Synthesis and evaluation of novel potent HCV NS5A inhibitors.

  2012cited by this paper
• Optimization of potent hepatitis C virus NS3 helicase inhibitors isolated from the yellow dyes thioflavine S and primuline.

  2012cited by this paper
• Mimicking the intramolecular hydrogen bond: synthesis, biological evaluation, and molecular modeling of benzoxazines and quinazolines as potential antimalarial agents.

  2012cited by this paper
• Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.

  2012cited by this paper
• Tri-substituted acylhydrazines as tertiary amide bioisosteres: HCV NS5B polymerase inhibitors.

  2012cited by this paper
• The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function

  2012cited by this paper
• Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase.

  2012cited by this paper
• A novel class of highly potent irreversible hepatitis C virus NS5B polymerase inhibitors.

  2012cited by this paper
• Discovery of flavonoid derivatives as anti-HCV agents via pharmacophore search combining molecular docking strategy.

  2012cited by this paper
• Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)

  2012cited by this paper
• Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity.

  2012cited by this paper
• Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase.

  2012cited by this paper
• Treating hepatitis C: current standard of care and emerging direct‐acting antiviral agents

  2012cited by this paper
• Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435.

  2012cited by this paper
• Effect on Hepatitis C Virus Replication of Combinations of Direct-Acting Antivirals, Including NS5A Inhibitor Daclatasvir

  2012cited by this paper
• Synthesis and SAR studies of novel heteroaryl fused tetracyclic indole-diamide compounds: potent allosteric inhibitors of the hepatitis C virus NS5B polymerase.

  2012cited by this paper
• Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease.

  2012cited by this paper
• Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series.

  2012cited by this paper
• Discovery of N‐Arylalkyl‐3‐hydroxy‐4‐oxo‐3,4‐dihydroquinazolin‐2‐carboxamide Derivatives as HCV NS5B Polymerase Inhibitors

  2012cited by this paper
• Hepatitis C virus host cell entry.

  2012cited by this paper
• Entry of hepatitis C virus into the cell: a therapeutic target.

  2012cited by this paper
• Integrated structure-based activity prediction model of benzothiadiazines on various genotypes of HCV NS5b polymerase (1a, 1b and 4) and its application in the discovery of new derivatives.

  2012cited by this paper
• Inhibition of hepatitis C virus NS5A by fluoro-olefin based γ-turn mimetics.

  2012cited by this paper
• Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase.

  2012cited by this paper
• HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamides.

  2012cited by this paper
• Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.

  2012cited by this paper
• Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).

  2012cited by this paper
• Characterization of COR627 and COR628, Two Novel Positive Allosteric Modulators of the GABAB Receptor

  2012cited by this paper
• Direct-acting and host-targeting HCV inhibitors: current and future directions.

  2012cited by this paper
• The changing therapeutic landscape for hepatitis C

  2012cited by this paper
• Hepatitis C Virus RNA Elimination and Development of Resistance in Replicon Cells Treated with BMS-790052

  2012cited by this paper
• Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors.

  2012cited by this paper
• Identification of aryl dihydrouracil derivatives as palm initiation site inhibitors of HCV NS5B polymerase.

  2012cited by this paper
• Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.

  2012cited by this paper
• TMC647055, a Potent Nonnucleoside Hepatitis C Virus NS5B Polymerase Inhibitor with Cross-Genotypic Coverage

  2012cited by this paper
• New hepatitis C virus drug discovery strategies and model systems

  2012cited by this paper
• Resistance Analysis and Characterization of a Thiazole Analogue, BP008, as a Potent Hepatitis C Virus NS5A Inhibitor

  2011cited by this paper
• Directly acting antivirals against hepatitis C virus.

  2011cited by this paper
• II. Novel HCV NS5B polymerase inhibitors: discovery of indole C2 acyl sulfonamides.

  2011cited by this paper
• Efficient In Silico Assay of Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase by Structure-Based Virtual Screening and In Vitro Evaluation

  2011cited by this paper
• Hepatitis C — pipeline update

  2011cited by this paper
• A new method for induced fit docking (GENIUS) and its application to virtual screening of novel HCV NS3-4A protease inhibitors.

  2011cited by this paper
• Inhibition of the helicase activity of the HCV NS3 protein by symmetrical dimeric bis-benzimidazoles.

  2011cited by this paper
• Discovery of potent nucleotide-mimicking competitive inhibitors of hepatitis C virus NS3 helicase.

  2011cited by this paper
• Biochemical Study of the Comparative Inhibition of Hepatitis C Virus RNA Polymerase by VX-222 and Filibuvir

  2011cited by this paper
• Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes.

  2011cited by this paper
• Synthesis and SAR optimization of diketo acid pharmacophore for HCV NS5B polymerase inhibition.

  2011cited by this paper
• Characterization of Resistance to the Nonnucleoside NS5B Inhibitor Filibuvir in Hepatitis C Virus-Infected Patients

  2011cited by this paper
• Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase

  2011cited by this paper
• Boceprevir: a user's guide.

  2011cited by this paper
• New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B.

  2011cited by this paper
• New HCV therapies on the horizon.

  2011cited by this paper
• Novel, potent, and orally bioavailable phosphinic acid inhibitors of the hepatitis C virus NS3 protease.

  2011cited by this paper
• Hepatitis C NS5B polymerase inhibitors: functional equivalents for the benzothiadiazine moiety.

  2011cited by this paper
• Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.

  2011cited by this paper
• Molecular modeling based approach, synthesis and in vitro assay to new indole inhibitors of hepatitis C NS3/4A serine protease.

  2011cited by this paper
• Nonstructural protein 3‐4A: the Swiss army knife of hepatitis C virus

  2011cited by this paper
• Discovery of Potent Hepatitis C Virus NS5A Inhibitors with Dimeric Structures

  2011cited by this paper
• Discovery of novel HCV polymerase inhibitors using pharmacophore-based virtual screening.

  2011cited by this paper
• Insight into the structural requirements of benzothiadiazine scaffold-based derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics.

  2011cited by this paper
• From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons.

  2011cited by this paper
• Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties.

  2011cited by this paper
• Boceprevir: A Protease Inhibitor for the Treatment of Chronic Hepatitis C

  2011cited by this paper
• Dimerization-driven interaction of hepatitis C virus core protein with NS3 helicase

  2011cited by this paper
• An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases

  2011cited by this paper
• Indole 5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase with nanomolar potency in cell-based subgenomic replicons (part 2): central amino acid linker and right-hand-side SAR studies.

  2011cited by this paper
• Ligand and structure based virtual screening strategies for hit-finding and optimization of hepatitis C virus (HCV) inhibitors.

  2011cited by this paper
• Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus.

  2011cited by this paper
• A macrocyclic HCV NS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target

  2011cited by this paper
• A Twenty-Eight-Day Mechanistic Time Course Study in the Rhesus Monkey with Hepatitis C Virus Protease Inhibitor BILN 2061

  2011cited by this paper
• I. Novel HCV NS5B polymerase inhibitors: discovery of indole 2-carboxylic acids with C3-heterocycles.

  2011cited by this paper
• Quinolones as HCV NS5B polymerase inhibitors.

  2011cited by this paper
• Computational analysis of de novo evolution of hepatitis C virus NS5B polymerase inhibitors.

  2011cited by this paper
• Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase.

  2011cited by this paper
• Inhibitors of hepatitis C virus polymerase: synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides.

  2010cited by this paper
• HCV NS5B polymerase inhibitors.

  2010cited by this paper
• Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease

  2010cited by this paper
• A Time-Resolved Fluorescence–Resonance Energy Transfer Assay for Identifying Inhibitors of Hepatitis C Virus Core Dimerization

  2010cited by this paper
• Combining Machine Learning and Pharmacophore-Based Interaction Fingerprint for in Silico Screening

  2010cited by this paper
• Combining 3-D Quantitative Structure-Activity Relationship with Ligand Based and Structure Based Alignment Procedures for in Silico Screening of New Hepatitis C Virus NS5B Polymerase Inhibitors

  2010cited by this paper
• Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

  2010cited by this paper
• Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups.

  2010cited by this paper
• Studies on the anti-hepatitis C virus activity of newly synthesized tropolone derivatives: identification of NS3 helicase inhibitors that specifically inhibit subgenomic HCV replication.

  2010cited by this paper
• Novel P2-P4 macrocyclic inhibitors of HCV NS3/4A protease by P3 succinamide fragment depeptidization strategy.

  2010cited by this paper
• Studies of benzothiadiazine derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics.

  2010cited by this paper

• Research Progress on the Protective Effect of Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate (EGCG) on the Liver

  2025cites this paper
• Structural Elucidation of Rift Valley Fever Virus L Protein towards the Discovery of Its Potential Inhibitors

  2022cites this paper
• In silico structural elucidation of RNA-dependent RNA polymerase towards the identification of potential Crimean-Congo Hemorrhagic Fever Virus inhibitors

  2019cites this paper
• RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution

  2018cites this paper
• Computational Modelling in Studies for Hepatitis C Virus (HCV) NS3 Protease.

  2016cites this paper
• Organic Carbamates in Drug Design and Medicinal Chemistry

  2015cites this paper
• Pharmacokinetics, Safety, and Tolerability of Faldaprevir in Patients with Renal Impairment

  2014cites this paper
• Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase.

  2014cites this paper
• Discovery of GPCR ligands for probing signal transduction pathways

  2014cites this paper
• Editorial: Rational design of antiviral compounds.

  2014cites this paper